“…It is one of the essential enzymes responsible for HCV viral replication and has attracted most attention as a potential therapeutic target [6]. In the past decade, there have been tremendous efforts dedicated to the development of novel, effective inhibitors of anti-HCV NS5B polymerase, and numerous classes of non-nucleoside inhibitors with different scaffolds have appeared in the literatures, such as benzimidazole [7][8][9], proline sulfonamide [10], indole [11][12][13][14], diketoacid [15][16][17], phenylalanine [18], thiophene [19], pyridazinone [20,21] and acrylic acid [22,23] and so on. Recently, a novel class of HCV NS5B polymerase inhibitors with thiazolone scaffold has been identified by the structurebased design method [24].…”